These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 30926649)
1. Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with Jadvar H; Velez EM; Desai B; Ji L; Colletti PM; Quinn DI J Nucl Med; 2019 Nov; 60(11):1524-1530. PubMed ID: 30926649 [TBL] [Abstract][Full Text] [Related]
2. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Pinski JK; Quinn DI J Nucl Med; 2013 Aug; 54(8):1195-201. PubMed ID: 23785174 [TBL] [Abstract][Full Text] [Related]
3. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with Wibmer AG; Morris MJ; Gonen M; Zheng J; Hricak H; Larson S; Scher HI; Vargas HA J Nucl Med; 2021 Aug; 62(8):1050-1056. PubMed ID: 33419944 [TBL] [Abstract][Full Text] [Related]
4. Increased Prostate Cancer Glucose Metabolism Detected by Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897 [TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
7. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923 [TBL] [Abstract][Full Text] [Related]
8. Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of [ Li A; Shen K; Ji Y; Zhang W; Liu B; Su R; Zhou X; Dong L; Zhu Y; Dong B; Pan J; Wang Q; Xue W Ann Med; 2024 Dec; 56(1):2411017. PubMed ID: 39392016 [TBL] [Abstract][Full Text] [Related]
10. A Comparison of Fourquet A; Rosenberg A; Mena E; Shih JJ; Turkbey B; Blain M; Bergvall E; Lin F; Adler S; Lim I; Madan RA; Karzai F; Gulley JL; Dahut WL; Wood BJ; Chang R; Levy E; Choyke PL; Lindenberg L J Nucl Med; 2022 May; 63(5):735-741. PubMed ID: 34475237 [No Abstract] [Full Text] [Related]
11. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer. Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586 [TBL] [Abstract][Full Text] [Related]
12. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. Fox JJ; Gavane SC; Blanc-Autran E; Nehmeh S; Gönen M; Beattie B; Vargas HA; Schöder H; Humm JL; Fine SW; Lewis JS; Solomon SB; Osborne JR; Veach D; Sawyers CL; Weber WA; Scher HI; Morris MJ; Larson SM JAMA Oncol; 2018 Feb; 4(2):217-224. PubMed ID: 29121144 [TBL] [Abstract][Full Text] [Related]
13. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262 [TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer. Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma. Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535 [TBL] [Abstract][Full Text] [Related]
16. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study. Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701 [TBL] [Abstract][Full Text] [Related]
17. Lymph node standardized uptake values at pre-treatment Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776 [TBL] [Abstract][Full Text] [Related]
18. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis. Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115 [TBL] [Abstract][Full Text] [Related]
19. Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma. Chun YJ; Jeung HC; Park HS; Park JS; Rha SY; Choi HJ; Lee JH; Jeon TJ Yonsei Med J; 2019 Jul; 60(7):604-610. PubMed ID: 31250573 [TBL] [Abstract][Full Text] [Related]
20. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]